Akèy › Kansè vejik › Ohio › Cincinnati
Etid klinik pou Kansè vejik nan Cincinnati, OH
10 etid pou Kansè vejik ap chèche patisipan nan sit nan ak bò kote Cincinnati (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- ak 3 plis
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Ap rekriteFaz 2
- TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122), Cincinnati
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Ap rekriteFaz 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi lwen
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Ap rekriteFaz 3
- Oncology Hematology Care Clinical Trials, LLC, Fairfield · 15 mi lwen
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Ap rekriteFaz 3
- TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822), Cincinnati
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- University of Cincinnati Medical Center, Cincinnati
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Ap rekriteFaz 2
- The Urology Group (Solaris), Cincinnati
- University of Cincinnati Cancer Center, Cincinnati
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- University of Cincinnati Medical Center (UCMC), Cincinnati
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Ap rekriteFaz 1/2
- University of Cincinnati Medical Center, Cincinnati
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Cincinnati
Etid Kansè vejik nan lòt vil
- New York City, NY35 etid
- Nashville, TN31 etid
- Houston, TX31 etid
- Dallas, TX27 etid
- Boston, MA26 etid
- Washington, DC26 etid
- Los Angeles, CA24 etid
- Baltimore, MD24 etid
- St. Louis, MO22 etid
- Philadelphia, PA21 etid
- Seattle, WA21 etid
- Edison, NJ21 etid
Lòt etid nan Cincinnati
- Kansè Poumon ki pa ti selil35 etid
- Kansè (tout kalite)27 etid
- Kansè nan tete25 etid
- Ensifizyans kadyak24 etid
- Kansè kolorektal21 etid
- Leksemi mieloïd egi20 etid
- Kansè Metastatik20 etid
- Kansè ovè19 etid
- Kansè poumon19 etid
- Obèsite19 etid
- Kansè pwostat18 etid
- Myelom Miltip17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.